Back to News
Market Impact: 0.35
Halozyme Therapeutics Unveils $1.05 Bln Offering Of Convertible Notes Due 2033
Source: Nasdaq
Credit & Bond MarketsCompany Fundamentals
Halozyme Therapeutics intends to offer $1.05 billion of convertible senior notes due 2033 and may grant initial purchasers a 13-day option to buy up to an additional $150 million. The financing could raise as much as $1.20 billion, strengthening liquidity but introducing potential future equity dilution and additional debt obligations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
HALO-0.15
More News
- Halozyme prices $1.3 billion convertible notes offering
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
- US to Sell F-35s to Saudi Arabia in $24.3 Billion Deal
- Why High Yields on Treasury Bonds, Government Debt Look Like the New Normal
- Fed rate decision and Warsh comments roiled markets. Where to find opportunities
- Crusoe raises $3.9B to build massive data centers and small modular “AI factories”